Trial Profile
Phase I study of rubitecan (RFS 2000) in the treatment of cancer patients with organ dysfunction.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Jan 2020
Price :
$35
*
At a glance
- Drugs Rubitecan (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Astex Pharmaceuticals
- 20 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 12 Oct 2009 Astex Pharmaceuticals added as trial sponsor as reported by ClinicalTrials.gov.
- 09 Sep 2005 New trial record.